ACCENTIA acquires and develops treatments for respiratory diseases, pain management, and cancer. Accentia has ten products on the market, including the Histex line of antihistamines and pain reliever XODOL. Its development-stage drugs include SinuNase, a potential treatment for sinus inflammation, and Biovaxid, vaccine for non-Hodgkin's lymphoma. In addition to its drug offerings, the company offers biologic manufacturing services, including cell-line development, purification, and viral validation. It also develops cell production instruments, including miniMAX, ResCu-Primer, and Xcellerator.
    Accentia operates in two segments: The Biopharmaceutical Products and Services segment develops late-stage products for respiratory and oncology diseases. The products are SinuNase and Biovaxid. The Specialty Pharmaceuticals segment, has a portfolio of 10 pharmaceutical products for licensing or co-development with other firms. The portfolio includes Xodol, Respi~TANN, a line of HISTEX products and two products that are co-promoted by the company. The Specialty Pharmaceuticals segment also has a pipeline of additional products developed through partners. Recently, the firm announced it has confidential agreements with several pharmaceutical companies for its SinuNase treatment for chronic sinusitis, a condition causing fluid buildup in sinuses.